Section Arrow
Quote
ALLO.NASDAQ
- Allogene Therapeutics
Quotes are at least 15-min delayed:2025/07/14 09:14 EDT
Pre Market
Last
 1.2801
+0.0001 (+0.01%)
Bid
1.27
Ask
1.3
High 1.34 
Low 1.28 
Volume 45433 
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
1.28 
1-M High
1.45 
Volume 
-- 
Bid
1.27
Ask
1.3
Day Low
-- 
Open
-- 
1-M Low
1.11 
Market Cap 
279.98M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.2 
20-SMA 1.24 
50-SMA 1.26 
52-W High 3.78 
52-W Low 0.8621 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.22/-1.19
Enterprise Value
363.22M
Balance Sheet
Book Value Per Share
1.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.00K
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
Pre Market 13.77 +0.43 +3.22%
ZVSAZyVersa Therapeutics----0.000%0PE
Pre Market 0.5624 -0.0276 -4.68%
ZVRAZevra Therapeutics----0.000%-- 
Pre Market 12.43 -0.1 -0.80%
ZURAZura Bio Limited----0.000%5.54PE
Pre Market 1.32 +0.01 +0.76%
ZNTLZentalis Pharmaceuticals----0.000%-- 
Pre Market 1.3049 -0.0251 -1.89%
Quotes are at least 15-min delayed：2025/07/14 09:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.